Anal cancer research hub

PHASE 1B/II TRIAL OF CHECKPOINT INHIBITOR (PEMBROLIZUMAB AND ANTI PD-1 ANTIBODY) PLUS STANDARD IMRT IN HPV INDUCED STAGE III SQUAMOUS CELL CARCINOMA OF ANUS

This study looks at a new way to treat anal cancer caused by HPV. It combines a standard radiation and chemotherapy treatment with a new drug called pembrolizumab (Keytruda). The main goal is to see if this combination treatment is safe and well-tolerated.